Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease

被引：7

作者：

Pusic, Iskra ^{[1
]}

Lee, Catherine ^{[2
]}

Veeraputhiran, Muthu ^{[3
]}

Minor, Chelsea ^{[1
]}

Dipersio, John F. ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63130 USA

[2] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA

[3] Univ Arkansas Med Sci, Dept Hematol & Med Oncol, Little Rock, AR USA

来源：

BONE MARROW TRANSPLANTATION | 2024年 / 59卷 / 02期

关键词：

THERAPIES;

D O I：

10.1038/s41409-023-02165-3

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：282 / 284

页数：3

共 12 条

[11] Three US Food and Drug Administration-approved therapies for chronic GVHD [J].

Zeiser, Robert ;

Lee, Stephanie J. .

BLOOD, 2022, 139 (11) :1642-1645

[12] Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease [J].

Zeiser, Robert ;

Polverelli, Nicola ;

Ram, Ron ;

Hashmi, Shahrukh K. ;

Chakraverty, Ronjon ;

Middeke, Jan Moritz ;

Musso, Maurizio ;

Giebel, Sebastian ;

Uzay, Ant ;

Langmuir, Peter ;

Hollaender, Norbert ;

Gowda, Maanasa ;

Stefanelli, Tommaso ;

Lee, Stephanie J. ;

Teshima, Takanori ;

Locatelli, Franco .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03) :228-238

← 1 2 →